- Six organisations: four institutes, one Industrial partner, one private company in charge of Management
- Three European Union member states involved
- Budget: €22,790,820 (IMI JU funding); EFPIA contribution: €27,920,073
- 6.5 year-duration: 1 December 2014 – 31 May 2021
-
About Us
- Ebovac2 in numbers
EBOVAC2 IN NUMBERS
NEWS
-
The Utility of a Two-Dose Ebola Vaccine Regimen Confirmed
In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of...
-
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
-
European Commission Approval for Janssen’s Ebola vaccine regimen
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
-
Positive CHMP Opinion for Janssen's Ebola Vaccine Regimen
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
-
Ebovac2 at ECCMID 2019
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
-
Ebola: background
What is Ebola?
-
Phase 2 trials
Find out more about EBOVAC2 trials
-
Work programme
EBOVAC2 is organised into 6 workpackages (WP)
-
Ebola+ programme
Contributes to efforts to tackle a wide range of challenges in Ebola research
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA